Semaglutide produced about 15% average body-weight loss in the STEP trials over 68 weeks (Wilding et al., N Engl J Med, 2021)
Elevated blood glucose and insulin levels after a meal dampen the GH response to secretagogues in studies, and a gap of several hours from the last carbohydrate-rich meal is repeatedly associated in the research literature with a clearer GH response
Cardiovascular prevention now forms a third revenue pillar after the 2024 FDA approval enabling semaglutide use in overweight adults with heart disease
If you are interested in hormone replacement therapy + weight-loss, your hormone consultation is included
For best results, take consistently as part of your daily routine AI-generated from the product information
Beyond Weight Loss: Other Health Benefits GLP-1 agonists influence extends beyond weight management, impacting several other health parameters beneficially